{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T22:39:44Z","timestamp":1795214384610,"version":"4.10.3"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.parkreldis.2025.108133","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:39:40Z","timestamp":1764117580000},"page":"108133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Protective or Pathogenic? Kinase activity and the neurodevelopmental origins of G2019S LRRK2-Associated Parkinson's disease"],"prefix":"10.1016","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1346-5443","authenticated-orcid":false,"given":"Emilia M.","family":"Gatto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto J.","family":"Espay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melisa","family":"Espindola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Da Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo A.","family":"Kauffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10423","key":"10.1016\/j.parkreldis.2025.108133_bib1","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(23)01419-8","article-title":"The epidemiology of Parkinson's disease","volume":"403","author":"Ben-Shlomo","year":"2024","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.parkreldis.2025.108133_bib2","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1093\/brain\/awae188","article-title":"Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study","volume":"147","author":"Westenberger","year":"2024","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.parkreldis.2025.108133_bib3","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3390\/genes13030471","article-title":"Monogenic Parkinson's Disease: Genotype, phenotype, pathophysiology, and genetic testing","volume":"13","author":"Jia","year":"2022","journal-title":"Genes (Basel)"},{"issue":"4","key":"10.1016\/j.parkreldis.2025.108133_bib4","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3390\/genes16040454","article-title":"Population-Specific differences in pathogenic variants of genes associated with monogenic Parkinson's Disease","volume":"16","author":"Flores-Ocampo","year":"2025","journal-title":"Genes (Basel)"},{"issue":"1","key":"10.1016\/j.parkreldis.2025.108133_bib5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1146\/annurev-biochem-030122-051144","article-title":"Leucine-Rich repeat kinases","volume":"93","author":"Alessi","year":"2024","journal-title":"Annu. Rev. Biochem."},{"issue":"1","key":"10.1016\/j.parkreldis.2025.108133_bib6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41531-025-00881-9","article-title":"Updated MDSGene review on the clinical and genetic spectrum of LRRK2 variants in Parkinson's disease","volume":"11","author":"Kr\u00fcger","year":"2025","journal-title":"npj Parkinson's Dis."},{"issue":"7","key":"10.1016\/j.parkreldis.2025.108133_bib7","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.3233\/JPD-230432","article-title":"How Parkinson's disease-linked LRRK2 mutations affect different CNS cell types","volume":"14","author":"Bailey","year":"2024","journal-title":"J. Parkinsons Dis."},{"issue":"1","key":"10.1016\/j.parkreldis.2025.108133_bib8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41531-023-00544-7","article-title":"Perspective on the current state of the LRRK2 field","volume":"9","author":"Taymans","year":"2023","journal-title":"npj Parkinson's Dis."},{"issue":"1","key":"10.1016\/j.parkreldis.2025.108133_bib9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00401-025-02871-w","article-title":"Abundant non-inclusion alpha-synuclein pathology in Lewy body-negative LRRK2-mutant cases","volume":"149","author":"Jensen","year":"2025","journal-title":"Acta Neuropathol."},{"issue":"1","key":"10.1016\/j.parkreldis.2025.108133_bib10","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00401-025-02872-9","article-title":"Widespread distribution of alpha-synuclein oligomers in LRRK2-related Parkinson's disease","volume":"149","author":"Sekiya","year":"2025","journal-title":"Acta Neuropathol."},{"issue":"2","key":"10.1016\/j.parkreldis.2025.108133_bib11","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/brain\/awae002","article-title":"Are we entering the 'Tau-lemaic' era of Parkinson's disease?","volume":"147","author":"Espay","year":"2024","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.parkreldis.2025.108133_bib12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s40478-019-0836-x","article-title":"Alzheimer's disease tau is a prominent pathology in LRRK2 Parkinson's disease","volume":"7","author":"Henderson","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"issue":"6","key":"10.1016\/j.parkreldis.2025.108133_bib13","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.cell.2020.08.004","article-title":"The in situ structure of parkinson's disease-linked LRRK2","volume":"182","author":"Watanabe","year":"2020","journal-title":"Cell"},{"issue":"46","key":"10.1016\/j.parkreldis.2025.108133_bib14","doi-asserted-by":"crossref","first-page":"16842","DOI":"10.1073\/pnas.0507360102","article-title":"Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity","volume":"102","author":"West","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"27","key":"10.1016\/j.parkreldis.2025.108133_bib15","doi-asserted-by":"crossref","first-page":"7128","DOI":"10.1523\/JNEUROSCI.3314-15.2016","article-title":"Altered development of synapse structure and function in striatum caused by Parkinson's disease-linked LRRK2-G2019S mutation","volume":"36","author":"Matikainen-Ankney","year":"2016","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.parkreldis.2025.108133_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109864","article-title":"The Parkinson's-disease-associated mutation LRRK2-G2019S alters dopaminergic differentiation dynamics via NR2F1","volume":"37","author":"Walter","year":"2021","journal-title":"Cell Rep."},{"issue":"29","key":"10.1016\/j.parkreldis.2025.108133_bib17","doi-asserted-by":"crossref","first-page":"17296","DOI":"10.1073\/pnas.1922184117","article-title":"Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity","volume":"117","author":"Nguyen","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"16","key":"10.1016\/j.parkreldis.2025.108133_bib18","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.3390\/ijms21165724","article-title":"The role of Alpha-Synuclein and other Parkinson's genes in neurodevelopmental and neurodegenerative disorders","volume":"21","author":"Morato Torres","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.parkreldis.2025.108133_bib19","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.73062","article-title":"The LRRK2 G2019S mutation alters astrocyte-to-neuron communication via extracellular vesicles and induces neuron atrophy in a human iPSC-derived model of Parkinson's disease","volume":"10","author":"de Rus Jacquet","year":"2021","journal-title":"eLife"},{"issue":"1","key":"10.1016\/j.parkreldis.2025.108133_bib20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12964-024-01997-w","article-title":"Loss of LRRK2 activity induces cytoskeleton defects and oxidative stress during porcine oocyte maturation","volume":"23","author":"Wei","year":"2025","journal-title":"Cell Commun. Signal."},{"issue":"4","key":"10.1016\/j.parkreldis.2025.108133_bib21","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.neuron.2017.09.036","article-title":"Age-dependent dopaminergic neurodegeneration and impairment of the autophagy-lysosomal pathway in LRRK-deficient mice","volume":"96","author":"Giaime","year":"2017","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.parkreldis.2025.108133_bib22","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40035-022-00285-2","article-title":"LRRK2 mutant knock-in mouse models: therapeutic relevance in Parkinson's disease","volume":"11","author":"Chang","year":"2022","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.parkreldis.2025.108133_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2025.1569733","article-title":"Roles of LRRK2 and its orthologs in protecting against neurodegeneration and neurodevelopmental defects","volume":"13","author":"Nguyen","year":"2025","journal-title":"Front. Cell Dev. Biol."},{"issue":"4","key":"10.1016\/j.parkreldis.2025.108133_bib24","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3390\/brainsci15040407","article-title":"The multifaceted role of LRRK2 in Parkinson's Disease","volume":"15","author":"Ho","year":"2025","journal-title":"Brain Sci."},{"issue":"1","key":"10.1016\/j.parkreldis.2025.108133_bib25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3390\/ijms25010111","article-title":"Molecular mechanisms of AMPA receptor trafficking in the nervous System","volume":"25","author":"Cao","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.parkreldis.2025.108133_bib26","doi-asserted-by":"crossref","DOI":"10.1111\/jnc.16265","article-title":"The kinase LRRK2 is required for the physiological function and expression of the glial glutamate transporter EAAT2 (SLC1A2)","volume":"169","author":"Di Iacovo","year":"2025","journal-title":"J. Neurochem."},{"key":"10.1016\/j.parkreldis.2025.108133_bib27","doi-asserted-by":"crossref","first-page":"RP92673","DOI":"10.7554\/eLife.92673.4","article-title":"Cell-autonomous role of leucine-rich repeat kinase in the protection of dopaminergic neuron survival","volume":"12","author":"Kang","year":"2024","journal-title":"eLife"},{"issue":"7","key":"10.1016\/j.parkreldis.2025.108133_bib28","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/s41419-023-05964-0","article-title":"LRRK2 phosphorylation status and kinase activity regulate (macro)autophagy in a RAB8a\/RAB10-dependent manner","volume":"14","author":"Kania","year":"2023","journal-title":"Cell Death Dis."},{"issue":"39","key":"10.1016\/j.parkreldis.2025.108133_bib29","doi-asserted-by":"crossref","first-page":"E9115","DOI":"10.1073\/pnas.1812196115","article-title":"LRRK2 and its substrate RAB GTPases are sequentially targeted onto stressed lysosomes and maintain their homeostasis","volume":"115","author":"Eguchi","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"18","key":"10.1016\/j.parkreldis.2025.108133_bib30","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020104494","article-title":"LRRK2 activation controls the repair of damaged endomembranes in macrophages","volume":"39","author":"Herbst","year":"2020","journal-title":"EMBO J."},{"issue":"1","key":"10.1016\/j.parkreldis.2025.108133_bib31","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41531-022-00289-9","article-title":"Mutant LRRK2 in lymphocytes regulates neurodegeneration via IL-6 in an inflammatory model of Parkinson's disease","volume":"8","author":"Kozina","year":"2022","journal-title":"npj Parkinson's Dis."},{"key":"10.1016\/j.parkreldis.2025.108133_bib32","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.31012","article-title":"Systematic proteomic analysis of LRRK2-mediated RAB GTPase phosphorylation establishes a connection to ciliogenesis","volume":"6","author":"Steger","year":"2017","journal-title":"eLife"},{"issue":"5","key":"10.1016\/j.parkreldis.2025.108133_bib33","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.3390\/cells9051115","article-title":"Alpha-Synuclein and LRRK2 in synaptic autophagy: linking early dysfunction to late-stage pathology in Parkinson's Disease","volume":"9","author":"Lamonaca","year":"2020","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.parkreldis.2025.108133_bib34","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13064-024-00193-3","article-title":"LRRK2 kinase activity is necessary for development and regeneration in Nematostella vectensis","volume":"19","author":"Holmes","year":"2024","journal-title":"Neural Dev."},{"issue":"164","key":"10.1016\/j.parkreldis.2025.108133_bib35","doi-asserted-by":"crossref","first-page":"164ra161","DOI":"10.1126\/scitranslmed.3004485","article-title":"Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations","volume":"4","author":"Sheng","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"30","key":"10.1016\/j.parkreldis.2025.108133_bib36","doi-asserted-by":"crossref","first-page":"14979","DOI":"10.1073\/pnas.1900289116","article-title":"The dynamic switch mechanism that leads to activation of LRRK2 is embedded in the DFG\u03c8 motif in the kinase domain","volume":"116","author":"Schmidt","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.parkreldis.2025.108133_bib37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41531-024-00660-y","article-title":"G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage","volume":"10","author":"Pe\u00f1a","year":"2024","journal-title":"npj Parkinson's Dis."},{"issue":"3","key":"10.1016\/j.parkreldis.2025.108133_bib38","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/mds.29343","article-title":"LRRK2-Targeting therapies March through the Valley of death","volume":"38","author":"West","year":"2023","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.parkreldis.2025.108133_bib39","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cpt.2277","article-title":"A disease progression model to quantify the non-motor symptoms of Parkinson's Disease in participants with leucine-rich repeat kinase 2 mutation","volume":"110","author":"Ahamadi","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"issue":"11","key":"10.1016\/j.parkreldis.2025.108133_bib40","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1001\/jamaneurol.2018.1885","article-title":"Frequency of loss of function variants in LRRK2 in parkinson disease","volume":"75","author":"Blauwendraat","year":"2018","journal-title":"JAMA Neurol."},{"issue":"10","key":"10.1016\/j.parkreldis.2025.108133_bib41","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/mds.27059","article-title":"Penetrance estimate of LRRK2 p.G2019S mutation in individuals of Non-Ashkenazi Jewish ancestry","volume":"32","author":"Lee","year":"2017","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.parkreldis.2025.108133_bib42","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/mds.27974","article-title":"Penetrance of Parkinson's Disease in LRRK2 p.G2019S carriers is modified by a polygenic risk Score","volume":"35","author":"Iwaki","year":"2020","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.parkreldis.2025.108133_bib43","first-page":"103","article-title":"Molecular mechanisms defining penetrance of LRRK2-associated Parkinson's disease","volume":"34","author":"Trinh","year":"2022","journal-title":"Med. Genet."},{"issue":"2","key":"10.1016\/j.parkreldis.2025.108133_bib44","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/hmg\/ddl471","article-title":"Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity","volume":"16","author":"West","year":"2007","journal-title":"Hum. Mol. Genet."},{"issue":"45","key":"10.1016\/j.parkreldis.2025.108133_bib45","doi-asserted-by":"crossref","first-page":"9700","DOI":"10.1523\/JNEUROSCI.1457-18.2018","article-title":"Parkinson's disease-linked LRRK2-G2019S mutation alters synaptic plasticity and promotes resilience to chronic social stress in young adulthood","volume":"38","author":"Matikainen-Ankney","year":"2018","journal-title":"J. Neurosci."},{"key":"10.1016\/j.parkreldis.2025.108133_bib46","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3389\/fnins.2020.00265","article-title":"Origins of Parkinson's Disease in brain development: insights from early and persistent effects of LRRK2-G2019S on striatal circuits","volume":"14","author":"Huntley","year":"2020","journal-title":"Front. Neurosci."},{"issue":"6","key":"10.1016\/j.parkreldis.2025.108133_bib47","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.neuron.2012.08.022","article-title":"LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis","volume":"75","author":"Matta","year":"2012","journal-title":"Neuron"},{"issue":"5","key":"10.1016\/j.parkreldis.2025.108133_bib48","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ijdevneu.2010.04.002","article-title":"Expression of leucine-rich-repeat-kinase 2 (LRRK2) during embryonic development","volume":"28","author":"Zechel","year":"2010","journal-title":"Int. J. Dev. Neurosci."},{"issue":"8","key":"10.1016\/j.parkreldis.2025.108133_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114574","article-title":"Neurofibrillary tangle-bearing neurons have reduced risk of cell death in mice with Alzheimer's pathology","volume":"43","author":"Zwang","year":"2024","journal-title":"Cell Rep."},{"issue":"6","key":"10.1016\/j.parkreldis.2025.108133_bib50","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1523\/JNEUROSCI.19-06-01959.1999","article-title":"RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease","volume":"19","author":"Nunomura","year":"1999","journal-title":"J. Neurosci."},{"issue":"9","key":"10.1016\/j.parkreldis.2025.108133_bib51","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1073\/pnas.0609303104","article-title":"Phosphorylation of tau antagonizes apoptosis by stabilizing beta-catenin, a mechanism involved in Alzheimer's neurodegeneration","volume":"104","author":"Li","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.parkreldis.2025.108133_bib52","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3389\/fneur.2020.00881","article-title":"Mitochondrial mechanisms of LRRK2 G2019S penetrance","volume":"11","author":"Delcambre","year":"2020","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.parkreldis.2025.108133_bib53","doi-asserted-by":"crossref","first-page":"16","DOI":"10.31083\/j.jin2301016","article-title":"The effect of p.G2019S mutation in the LRRK2 gene on the activity of lysosomal hydrolases and the clinical features of Parkinson's Disease associated with p.N370S mutation in the GBA1 gene","volume":"23","author":"Usenko","year":"2024","journal-title":"J. Integr. Neurosci."},{"issue":"14","key":"10.1016\/j.parkreldis.2025.108133_bib54","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1113\/JP276163","article-title":"Leucine rich repeat kinase 2: a paradigm for pleiotropy","volume":"597","author":"Lewis","year":"2019","journal-title":"J. Physiol."},{"issue":"8","key":"10.1016\/j.parkreldis.2025.108133_bib55","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1474-4422(23)00205-3","article-title":"Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial","volume":"22","author":"Giladi","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2025.108133_bib56","article-title":"Plasma glucosylceramide levels are regulated by ATP10D and are not involved in Parkinson's disease pathogenesis","volume":"2024","author":"Somerville","year":"2024","journal-title":"Preprint. medRxiv"},{"issue":"9475","key":"10.1016\/j.parkreldis.2025.108133_bib57","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/S0140-6736(05)66552-X","article-title":"Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months","volume":"365","author":"Edwards","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.parkreldis.2025.108133_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2024.106522","article-title":"LRRK2 kinase inhibition protects against Parkinson's disease-associated environmental toxicants","volume":"196","author":"Ilieva","year":"2024","journal-title":"Neurobiol. Dis."},{"issue":"9","key":"10.1016\/j.parkreldis.2025.108133_bib59","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1080\/13543776.2024.2378076","article-title":"Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson's disease: a patent review of the literature to date","volume":"34","author":"Morez","year":"2024","journal-title":"Expert Opin. Ther. Pat."},{"issue":"7","key":"10.1016\/j.parkreldis.2025.108133_bib60","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1212\/WNL.0000000000006926","article-title":"Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases","volume":"92","author":"Espay","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2025.108133_bib61","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/B978-0-323-85555-6.00001-1","article-title":"The shift to a proteinopenia paradigm in neurodegeneration","volume":"193","author":"Ezzat","year":"2023","journal-title":"Handb. Clin. Neurol."},{"issue":"1","key":"10.1016\/j.parkreldis.2025.108133_bib62","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41531-023-00468-2","article-title":"LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts","volume":"9","author":"Merchant","year":"2023","journal-title":"npj Parkinson's Dis."},{"key":"10.1016\/j.parkreldis.2025.108133_bib63","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40478-017-0492-y","article-title":"Elevated LRRK2 autophosphorylation in brain-derived and peripheral exosomes in LRRK2 mutation carriers","volume":"5","author":"Wang","year":"2017","journal-title":"Acta Neuropathol. Commun."},{"issue":"3","key":"10.1016\/j.parkreldis.2025.108133_bib64","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00401-021-02325-z","article-title":"R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils","volume":"142","author":"Fan","year":"2021","journal-title":"Acta Neuropathol."},{"issue":"3","key":"10.1016\/j.parkreldis.2025.108133_bib65","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/mds.29297","article-title":"LRRK2 inhibition by BIIB122 in healthy participants and patients with Parkinson's Disease","volume":"38","author":"Jennings","year":"2023","journal-title":"Mov. Disord."}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135380202500882X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135380202500882X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T16:49:37Z","timestamp":1768841377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135380202500882X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":65,"alternative-id":["S135380202500882X"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2025.108133","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protective or Pathogenic? Kinase activity and the neurodevelopmental origins of G2019S LRRK2-Associated Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2025.108133","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108133"}}